Akums Drugs & Pharmaceuticals Merger & Restructuring Worth ₹56 Cr

Akums Drugs & Pharmaceuticals Earnings Call Transcript: Key Takeaways

Consolidated revenue ₹1,342 Cr (+31.9% YoY) and EBITDA ₹195 Cr (+106%), led by CDMO volumes. Management gave no numeric guidance. API still loss-making and domestic branded growth is only about 8%.

Akums Drugs & Pharmaceuticals Other Announcement

Akums Drugs and Pharmaceuticals Limited has fully utilized its IPO proceeds totaling Rs. 680 Crore as of September 30, 2026. Consequently, further monitoring agency reports are no longer required.

Value

₹680.0 Cr

Akums Drugs & Pharmaceuticals Investor Presentation: Key Takeaways

Q2 FY27: revenue INR 1,342 cr (+31.9% YoY), EBITDA INR 195 cr (14.5% margin), PAT INR 115 cr (+168.3% YoY). CDMO-led growth; API losses narrowing.

Akums Drugs & Pharmaceuticals Results Update

Akums reported Q2 FY27 revenue of ₹1,342 crore, up 31.9%, and PAT of ₹115 crore, up 168%. The release is a press update with highlights, not the full results statement.

Akums Drugs & Pharmaceuticals Q2 FY27 Results: Net Profit ₹114.6 Cr, Up 168.4% YoY

Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,342 Cr (+31.9% YoY) and net profit of ₹114.6 Cr (+168.4% YoY) for Q2 FY27.

Key figure

Net profit ₹114.6 Cr · +168.4% YoY

Akums Drugs & Pharmaceuticals Management Change

Akums Drugs announced the resignation of Mr. Sunil Jaiswal, SVP R&D and Senior Management Personnel, effective 31 October 2026. The resignation was submitted on 5 August 2026 citing family commitments.

Aurobindo Pharma Merger & Restructuring Worth ₹29 Cr

Aurobindo Pharma approved transferring 100% of Auro Pharma LLC, Russia, between wholly owned subsidiaries. Cash consideration is about INR 29 crore, subject to adjustments.

Value

₹29.00 Cr

Execution

60-90 days

Choice International Merger & Restructuring Worth ₹1.27 Cr

Choice International sold a unit or subsidiary to Arrowbridge Trade for Rs.1.275 Crore in cash. The buyer is unrelated and the deal is at arm's length.

Value

₹1.27 Cr

Shringar House of Mangalsutra Merger & Restructuring Worth ₹5 Cr

Shringar House of Mangalsutra will incorporate a wholly owned jewellery subsidiary, subscribing Rs 5 Crore in cash. The subsidiary becomes a related party once formed.

Value

₹5.00 Cr

HEG Advanced Materials Merger & Restructuring Worth ₹10.12 Cr

HEG Advanced Materials closed LNJ Trading FZCO, its Dubai-based wholly owned subsidiary, as part of overseas structure rationalisation. The filing quantifies the effect at AED 4,048,000.

Value

₹10.12 Cr

Saregama India Merger & Restructuring

Saregama India's board approved closing its wholly owned Dubai subsidiary, Saregama FZE, which has no ongoing operations. The closure is not expected to materially affect business operations.

Jindal Poly Films Merger & Restructuring

Jindal Poly Films' step-down subsidiary, JPF API Laminates UK Limited, was dissolved effective November 3, 2026. It has ceased to be a subsidiary of the company.